Testing effectiveness (Phase 2)Ended earlyNCT05119335
What this trial is testing
NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Who this might be right for
ccRCCClear Cell Renal Cell CarcinomaKidney Cancer+14 more
NiKang Therapeutics, Inc. 120